Ignite Creation Date:
2024-05-06 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 12:44 PM
Study NCT ID:
NCT03504163
Status:
RECRUITING
Last Update Posted:
2024-06-25
First Post:
2018-04-11
Brief Title:
Pembrolizumab MK-3475 and Bacillus Calmette-Guérin BCG as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer NMIBC and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma NMI-UTUC
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center